Eliquis, manufacturer Bristol-Myers Squibb, has notified the Food and Drug Administration (FDA) of a Voluntary Recall of a lot of Eliquis 5 mg tablets. Eliquis, manufacturer Bristol-Myers Squibb, has notified the Food and Drug Administration (FDA) of a Voluntary Recall of a lot of Eliquis 5 mg tablets packaged in 60-count bottles (lot HN0063, Exp 09/2019, NDC 0003-0894-21). According to the manufacture bottles of the recalled lot was distributed Nationwide in the U.S. to wholesalers and retail pharmacies in February 2017. Bristol-Myers Squibb has issued the Voluntary Recall of Eliquis as a precautionary measure based on a customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. Eliquis is prescribed to people that have atrial fibrillation and is used to reduce the risk of stroke and blood clots. Eliquis is also prescribed to treats blood clots in the veins of your legs or lungs as well as reduces the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery. If you have filled prescriptions for Eliquis 5 mg tablets and have related concerns contact your prescription, you should contact your pharmacy or prescribing physician. For more information about the Voluntary Recall of Eliquis, visit the FDA website at https://www.fda.gov/Safety/Recalls/ucm563002.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
0 comments on "Nationwide Voluntary Drug Recall for Eliquis 5 mg tablets, lot HN0063"